Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that the clinical trial application (CTA) for HY3003 tablets has been accepted by China’s National Medical Products Administration (NMPA) — advancing an oral, once‑daily formulation of the company’s GLP‑1R/GIPR/GCGR triple receptor agonist, a Class 1 chemical drug intended for weight loss, type 2 diabetes, and metabolic dysfunction‑associated steatohepatitis (MASH).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Action | Acceptance of clinical trial application |
| Product | HY3003 tablets |
| Modality | Small‑molecule/oral GLP‑1R/GIPR/GCGR triple receptor agonist |
| Drug Classification | Class 1 chemical drug |
| Intended Indications | Weight loss; type 2 diabetes; metabolic dysfunction‑associated steatohepatitis (MASH) |
| Announcement Date | 6 Nov 2026 |
| Next Steps | Clinical trial conduct following CTA acceptance; trial design details not disclosed |
Drug Profile & Mechanism of Action
- Molecule: HY3003 — a triple receptor agonist simultaneously targeting GLP‑1R (glucagon‑like peptide‑1 receptor), GIPR (glucose‑dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor).
- Triple‑Agonist Rationale: Engaging all three receptors combines the established incretin biology of GLP‑1 and GIP with glucagon‑receptor signaling — a mechanism class associated with energy expenditure and hepatic lipid metabolism — positioning HY3003 within the frontier of next‑generation cardiometabolic drug design.
- Parallel Multi‑Formulation Strategy: The HY3003 program adopts a parallel multi‑formulation development strategy, covering three complementary directions:
- HY3003 injection – weekly formulation
- HY3003 sustained‑release injection – monthly formulation
- HY3003 tablets – once‑daily oral formulation
- Broad Indication Ambition: A single molecular entity is being developed across three major metabolic indications — obesity/weight loss, type 2 diabetes, and MASH — maximizing platform value from one asset.
- Preclinical Pharmacodynamics: Preclinical study results demonstrated that HY3003 tablets exhibited clear, dose‑dependent weight reduction effects in both DIO (diet‑induced obesity) mouse and DIO rat obesity models.
Competitive Landscape – Cardiometabolic Triple Agonists
- Hot Mechanism Class: GLP‑1R/GIPR/GCGR triple agonism is among the most actively pursued mechanisms in obesity and metabolic disease drug development, following the commercial transformation of the incretin class.
- Oral Differentiation: An once‑daily oral tablet addresses the convenience and scalability limitations of injectable regimens — a key battleground as the weight‑loss market expands toward broader primary‑care populations.
- Multi‑Route Coverage: Hybio’s parallel strategy — weekly injection, monthly sustained‑release injection, and daily oral tablet — aims to serve diverse patient preferences and adherence profiles across the treatment journey.
- MASH Opportunity: Inclusion of MASH among intended indications taps a large, historically difficult‑to‑treat liver disease population where metabolic‑targeted therapies are gaining regulatory traction.
- Stage Note: This is an early‑stage clinical milestone; human safety, pharmacokinetic, and efficacy data for HY3003 tablets have not yet been disclosed.
Market Impact & Outlook
- Pipeline Advancement: NMPA CTA acceptance moves HY3003 tablets into the clinical phase, a concrete regulatory checkpoint for Hybio’s cardiometabolic innovation strategy.
- Class 1 Innovation Status: Classification as a Class 1 chemical drug underscores the novelty of the molecule within China’s regulatory framework for new chemical entities.
- Portfolio Synergy: The triple‑agonist program complements Hybio’s existing pharmaceutical franchise, extending the company’s footprint into the high‑growth obesity and metabolic disease markets.
- Next Catalysts: First‑in‑human trial initiation and readouts for HY3003 tablets, clinical progression of the weekly and monthly injectable formulations, and dose‑ranging efficacy signals in weight reduction.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory progression, and therapeutic potential of HY3003 across its tablet, weekly injection, and sustained‑release injection formulations. Acceptance of a clinical trial application does not guarantee trial outcomes or future marketing approval. Actual results may differ due to risks including first‑in‑human safety and tolerability findings, clinical trial execution, translation of preclinical weight‑reduction effects to humans, regulatory review requirements, and intense competitive dynamics in the GLP‑1‑based cardiometabolic drug class.-Fineline Info & Tech
